Treatment of kidney cancer
Abstract
Germline inactivation of theVHLtumor suppressor gene is associated with an increased risk of clear cell carcinoma of the kidney in the context of von Hippel‐Lindau (VHL) disease. SomaticVHLmutations are also common in nonhereditary (sporadic) clear cell carcinomas. The VHL protein (pVHL) has multiple functions that might be linked to tumor suppression, including targeting the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. HIF, especially HIF2α, appears to play a causal role in clear cell renal carcinogenesis based on genotype‐phenotype correlations in VHL disease, laboratory experiments with humanVHL−/− renal carcinoma cell lines, and genetically engineered mouse models. Deregulation of HIF almost certainly accounts for the high levels of vascular endothelial growth factor (VEGF) observed in kidney cancer and relates to their sensitivity to VEGF inhibitors. In addition, the beneficial effects of mammalian target of rapamycin (mTOR) inhibitors are likely due to, at least partly, their ability to down‐regulate HIF. pVHL, in a HIF‐independent manner, also regulates a specialized structure called the primary cilium and regulates apoptosis via factors such as NFκB. Loss of the primary cilium probably facilitates the development of preneoplastic renal cysts, whereas increased NFκB might contribute to the resistance of kidney cancers to conventional cytotoxic agents. Cancer 2009;115(10 suppl):2262‐72. © 2009 American Cancer Society.Keywords
Funding Information
- Genentech, Novartis Pharmaceuticals, Pfizer, Inc., and Wyeth Pharmaceuticals
This publication has 102 references indexed in Scilit:
- pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formationThe EMBO Journal, 2008
- Hypoxia-inducible factor-2 regulates vascular tumorigenesis in miceOncogene, 2008
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase PathwayMolecular Cell, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2Molecular Cell, 2007
- pVHL and GSK3β are components of a primary cilium-maintenance signalling networkNature Cell Biology, 2007
- RACK1 Competes with HSP90 for Binding to HIF-1α and Is Required for O2-Independent and HSP90 Inhibitor-Induced Degradation of HIF-1αMolecular Cell, 2007
- Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivoThe EMBO Journal, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005